Nisha Quasba joins Ethics Talk to discuss her article, coauthored with Elliot Vice: “What Should Prescribers and Policy Makers Know About US Drug Importation?”
Dr Amy B. Cadwallader joins Ethics Talk to discuss her article, coauthored with Kavitha Nallathambi: “How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?”
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.
Jodi Halpern, MD, PhD and Richard L. Kravitz, MD, MSPH
Just as people frequently support political parties without endorsing their entire platforms, perhaps physicians can support a health care advocacy organization without agreeing with its screening guidelines.
AMA Journal of Ethics' editor Audiey Kao, MD, PhD, interviewed Kenneth Sands, MD, about harms to patient dignity caused by unintentional disrespect and about initiatives for measuring, tracking, and correcting such harms.
The high price of cancer drugs in the US relative to European countries with universal health care raises ethical issues of access, financial burden on patients, and unsustainability of the health care system.
AMA J Ethics. 2015;17(8):750-753. doi:
10.1001/journalofethics.2015.17.8.nlit1-1508.